Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2025

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of Reconciliation of the Activity Affecting Intangible Assets

A reconciliation of the activity affecting intangible assets, net for each of 2025 and 2024 is as follows:


	Year Ended March 31, 2025
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2024	$	2,167,162	$	411,258	$	2,578,420
Additions (a)	6,850		1,400		8,250
Reclassifications (b)	(28,982)		28,982		—

Tradename impairment	(6,552)		(5,914)		(12,466)
Effects of foreign currency exchange rates	(1,492)		(1,226)		(2,718)
Balance – March 31, 2025	$	2,136,986	$	434,500	$	2,571,486

Accumulated Amortization
Balance – March 31, 2024	$	—	$	257,837	$	257,837
Additions	—		18,263		18,263

Effects of foreign currency exchange rates	—		36		36
Balance – March 31, 2025	$	—	$	276,136	$	276,136

Intangible assets, net – March 31, 2025	$	2,136,986	$	158,364	$	2,295,350

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,068,752	$	141,234	$	2,209,986
International OTC Healthcare	68,234		17,130		85,364

Intangible assets, net – March 31, 2025	$	2,136,986	$	158,364	$	2,295,350

(a) Amounts relate to our acquisition of Hydralyte intellectual property on October 1, 2024, giving us the rights to the Hydralyte intellectual property in all remaining jurisdictions with the exception of the United States.

(b) In connection with our annual impairment test at February 28, 2025, certain indefinite-lived intangible assets were moved to finite-lived to better reflect our long-term projections for these brands.


	Year Ended March 31, 2024
(In thousands)	Indefinite- Lived Tradenames		Finite-Lived Tradenames and Customer Relationships		Totals
Gross Carrying Amounts
Balance – March 31, 2023	$	2,168,902	$	411,118	$	2,580,020
Additions (a)	393		680		1,073



Effects of foreign currency exchange rates	(2,133)		(540)		(2,673)
Balance – March 31, 2024	$	2,167,162	$	411,258	$	2,578,420

Accumulated Amortization
Balance – March 31, 2023	$	—	$	238,127	$	238,127
Additions	—		19,784		19,784

Effects of foreign currency exchange rates	—		(74)		(74)
Balance – March 31, 2024	$	—	$	257,837	$	257,837

Intangible assets, net – March 31, 2024	$	2,167,162	$	153,421	$	2,320,583

Intangible Assets, net by Reportable Segment:
North American OTC Healthcare	$	2,092,853	$	135,932	$	2,228,785
International OTC Healthcare	74,309		17,489		91,798

Intangible assets, net – March 31, 2024	$	2,167,162	$	153,421	$	2,320,583

(a) On January 8, 2024, our Australian subsidiary acquired one of its suppliers. In connection with this acquisition, we allocated $1.1 million to intangible assets.

Schedule of Expected Amortization Expense

At March 31, 2025, finite-lived intangible assets are expected to be amortized over their estimated useful lives, which ranges from a period of 10 to 24 years, and the estimated amortization expense for each of the five succeeding years and periods thereafter is as follows (in thousands):


(In thousands)
Year Ending March 31,	Amount
2026	$	17,192
2027	15,602
2028	13,277
2029	13,277
2030	13,277
Thereafter	85,739
	$	158,364